WuXi Biologics and Vertex reach licensing and research service agreement for innovative trispecific T-cell engager

格隆汇2026/02/03 00:51

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Gelonghui, February 3rd｜WuXi Biologics announced that it has signed a licensing and research services agreement with Vertex Pharmaceuticals (NASDAQ: VRTX) for an innovative trispecific T-cell engager (TCE). Vertex plans to use it for the treatment of B cell-mediated autoimmune diseases. Under the terms of the agreement, Vertex will obtain global exclusive rights for the development and commercialization of this preclinical-stage trispecific TCE intended for the treatment of B cell-mediated autoimmune diseases. WuXi Biologics will receive an upfront payment and is eligible to receive milestone payments related to development, registration, and sales, as well as royalties on product sales after launch. In addition, WuXi Biologics will provide integrated contract research and development services for its innovative TCE.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to Freddie Mac data, the 30-year fixed mortgage rate has risen to 7.4%, the highest level in nearly three years. Data from real estate brokerage Redfin shows that the volume of existing home pending sales in September fell 4% month-on-month, marking the largest single-month drop in over three years and hitting the lowest level since 2014. Nearly one-fifth of sellers have reduced prices, and the home purchase contract cancellation rate has reached a record high of 14.5%. Inventory levels have risen to the highest since March 2020, but high financing costs continue to constrain transactions.

华尔街见闻•2026/10/12 20:41